Pericardial synovial sarcoma: 14-year survival with multimodality therapy

Ann Thorac Surg. 2004 Sep;78(3):e41-2. doi: 10.1016/j.athoracsur.2004.02.011.

Abstract

We report a case of recurrent primary synovial sarcoma of the pericardium. Reverse transcriptase-polymerase chain reaction analysis for t(X,18) demonstrated the presence of the chimeric transcript SYT/SSX. Because of the rarity of this entity, optimal therapy is unknown. The prognosis of this tumor is very poor in previous reports. In this report, we present a case with five recurrences treated by a combination of surgery, chemotherapy, and radiotherapy. The patient survives now for more than 14 years, the longest reported survival of a primary synovial sarcoma of the pericardium.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Chemotherapy, Adjuvant
  • Dimethoate / administration & dosage
  • Disease Progression
  • Doxorubicin / administration & dosage
  • Drug Administration Schedule
  • Humans
  • Ifosfamide / administration & dosage
  • Isoquinolines / administration & dosage
  • Magnetic Resonance Imaging
  • Male
  • Mediastinal Neoplasms / diagnosis
  • Mediastinal Neoplasms / drug therapy*
  • Mediastinal Neoplasms / pathology
  • Mediastinal Neoplasms / surgery*
  • Neoplasm Recurrence, Local / diagnosis*
  • Neoplasm Recurrence, Local / therapy*
  • Neoplasm, Residual / drug therapy
  • Neoplasm, Residual / surgery
  • Palliative Care
  • Pericardium / diagnostic imaging
  • Sarcoma, Synovial / diagnosis
  • Sarcoma, Synovial / drug therapy*
  • Sarcoma, Synovial / pathology
  • Sarcoma, Synovial / surgery*
  • Tomography, X-Ray Computed
  • Treatment Outcome

Substances

  • Isoquinolines
  • ecteinascidin 729
  • Doxorubicin
  • Ifosfamide
  • Dimethoate